Skip to content Skip to footer
Subscribe Now

NEWS

Y-Mabs
SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics for ~$412M
Shots: SERB Pharmaceuticals has entered into a definitive merger agreement to acquire Y-mAbs, incl. its asset Danyelza (naxitamab-gqgk), strengthening its rare oncology portfolio As per the deal, SERB will acquire Y-mAbs for a total equity value of ~$412M, with its shareholders receiving $8.6/share in cash, delisting Y-mAbs from Nasdaq; closing expected in Q4’25 Additionally, Y-mAbs’ pipeline incl.…
August 6, 2025
Ethris Reports First Patient Dosing in P-IIa Trial of ETH47 for Asthma
Shots: Ethris has dosed the first pts in a P-IIa trial of ETH47 for asthma symptom reduction after rhinovirus challenge, building on P-I trial data, which showed strong respiratory tract activity, local IFNλ induction, antiviral gene activation, & no systemic exposure The P-IIa trial will evaluate ETH47 vs PBO in ~50 adults with asthma who…
August 5, 2025
Alcon to Acquire STAAR Surgical Company for ~$1.5B
Shots: Alcon has entered into a definitive merger agreement to acquire STAAR Surgical Company incl. its asset EVO family of lenses (EVO ICL) As per the deal, Alcon will acquire STAAR for a total equity value of ~$1.5B, with its shareholders receiving $28/share in cash; the deal is expected to close within 6-12mos. EVO ICLs are…
August 5, 2025
AliveDx Receives the CE Mark Approval for MosaiQ AiPlex VAS Assay to Diagnose Autoimmune Vasculitis
Shots: AliveDx has received the European IVDR-CE mark approval for MosaiQ AiPlex Vasculitis (VAS) assay to improve & accelerate diagnosis of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides & Anti-GBM (Goodpasture's) disease VAS assay diagnoses autoimmune vasculitis using just 10μL of sample in a single test, with 3 key autoantibody markers: MPO, PR3, & GBM VAS assay allows accurate serological evaluation with…
August 5, 2025
CivicaScript is set to distribute Ustekinumab-aauz  (Biosimilar, Stelara) for Chronic Inflammatory Conditions 
Shots:  CivicaScript announced plans to distribute the biosimilar ustekinumab-aauz for CICs incl. plaque PsO, PsA, Crohn’s disease, and ulcerative colitis, with its launch anticipated on Jan 01, 2026  Ustekinumab-aauz targets IL-12 & 23, helping regulate immune and inflammatory responses. Produced by Fresenius Kabi, it will be exclusively distributed by CivicaScript in the US and is interchangeable with…
August 5, 2025
Turbine Collaborates with Merck to Use AI-Driven Tumor Simulation for Identifying Novel Targets in Hard-to-Treat Cancers
Shots: Turbine has entered into a research collaboration with Merck to simulate hard-to-treat cancer pts populations that are challenging to study in traditional lab settings As per the deal, Meck will leverage Turbine's Simulated Cells to develop virtual tumor models that mimic hard-to-study, treatment-resistant subtypes to validate novel targets, biomarkers, & combination therapies Collaboration includes…
August 4, 2025
Load more